Matt Larew
Stock Analyst at William Blair
(0.45)
# 4,141
Out of 5,005 analysts
13
Total ratings
37.5%
Success rate
-26.11%
Average return
Main Sectors:
Stocks Rated by Matt Larew
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Initiates: Outperform | n/a | $543.32 | - | 1 | Aug 19, 2025 | |
| MXCT MaxCyte | Downgrades: Market Perform | n/a | $1.71 | - | 2 | Aug 7, 2025 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Market Perform | n/a | $3.09 | - | 1 | Nov 8, 2024 | |
| DNA Ginkgo Bioworks Holdings | Downgrades: Underperform | n/a | $16.14 | - | 3 | May 10, 2024 | |
| ATR AptarGroup | Upgrades: Outperform | n/a | $133.22 | - | 1 | Apr 29, 2024 | |
| TECH Bio-Techne | Initiates: Outperform | n/a | $62.95 | - | 1 | Aug 28, 2023 | |
| AVTR Avantor | Downgrades: Market Perform | n/a | $14.29 | - | 1 | Jul 31, 2023 | |
| INNV InnovAge Holding | Downgrades: Market Perform | n/a | $5.01 | - | 2 | Sep 22, 2021 | |
| TWST Twist Bioscience | Initiates: Outperform | n/a | $31.07 | - | 1 | Jun 29, 2021 |
Thermo Fisher Scientific
Aug 19, 2025
Initiates: Outperform
Price Target: n/a
Current: $543.32
Upside: -
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.71
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.09
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $16.14
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $133.22
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $62.95
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $14.29
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $5.01
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $31.07
Upside: -